LEXEO Therapeutics Company

LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Industry: Clinical Development, Early Drug Development, Preclinical Development
Headquarters: New York, New York, United States
Founded Date: 2018-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 16
Total Funding: 185000000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-09-09
Last Funding Type: Series B

Visit Website
info@lexeotx.com
Register and Claim Ownership